

Approved for use through 06/30/2006. OMB 0651-0031


U.S. Patent and Trademark Office 11 S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Complete if Known

Application Number	10/764,833
Filing Date	January 27, 2004
First Named Inventor	AYALON-SOFFER Michal et al
Group Art Unit	1631
Examiner Name	P. WNAVEY

Sheet	1	Of	3	Attorney Docket Number
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
PW		Naka et al, "The paradigm of IL-6: from basic science to medicine" Arthritis Res. 2002;4 Suppl 3:S233-42. Epub 2002 May 09. Review		
PW		Furge et al, "Met receptor tyrosine kinase: enhanced signaling through adapter proteins" Oncogene. 2000 Nov 20;19(49):5582-9.		
PW		Deonarain et al, "Interferon-alpha/beta-receptor interactions: a complex story unfolding", Curr Pharm Des. 2002;8(24):2131-7.		
PW		Blazar et al, "Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients", J Immunol. 2001 Mar 1;166(5):3174-83.		
PW		Fry et al, "Interleukin-7: from bench to clinic", Blood. 2002 Jun 1;99(11):3892-904		
PW		Attasano et al, "Signal transduction by the TGF-beta superfamily", Science. 2002 May 31;296(5573):1646-7.		
PW		Kerr et al, "Small molecule alpha(v) integrin antagonists: novel anticancer agents", Expert Opin Investig Drugs. 2000 Jun;9(6):1271-9.		
PW		To et al, "The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review)", Oncol Rep. 1998 Sep-Oct;5(5):1013-24		
PW		Simpson et al, "Interleukin-6: structure-function relationships", Protein Sci. 1997 May;6(5):929-55.		
PW		Cosenza et al, "Comparative model building of interleukin-7 using interleukin-4 as a template: a structural hypothesis that displays atypical surface chemistry in helix D important for receptor activation", Protein Sci. 2000 May;9(5):916-26.		
PW		Comoglio et al, "Invasive growth: from development to metastasis", J Clin Invest. 2002 Apr;109(7):857		
PW		Brierley et al, "IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry", J Interferon Cytokine Res. 2002 Aug;22(8):835-45.		
PW		Aggarwal, BB, "Signalling pathways of the TNF superfamily: a double-edged sword", Nat Rev Immunol. 2003 Sep;3(9):745-56		
PW		Tucker, GC, "αv Integrin inhibitors and cancer therapy", Curr Opin Invest Drugs, 4(6):722-731,2003		
PW		Nelms et al, "The IL-4 receptor: signaling mechanisms and biologic functions", Annu Rev Immunol. 1999;17:701-38		
PW		Moor et al, "Interleukin-10 and the interleukin-10 receptor", Annu Rev Immunol. 2001;19:683-765.		
PW		Pan et al, "IL-4 receptor mutations", Curr Opin Immunol. 1999 Dec;11(6):615-20.		
PW		Seo et al, "Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis", J Immunol. 2003 Jul 15;171(2):576-83.		
PW		Vinay et al, "Role of 4-1BB in immune responses", Semin Immunol. 1998 Dec;10(6):481-9.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>. Applicant's unique citation designation number (optional). <sup>2</sup>. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known


Application Number	10/764,833
Filing Date	January 27, 2004
First Named Inventor	AYALON-SOFFER Michal et al
Group Art Unit	1631
Examiner Name	P. WANNISY

Sheet	2	Of	3	Attorney Docket Number
PW		Zhang et al "HGF/SF-met signaling in the control of branching morphogenesis and invasion", J Cell Biochem. 2003 Feb 1;88(2):408-17.		
PW		Walter, MR. "Strucure of interleukin-10/interleukin-10R1 complex: a paradigm for class 2 cytokine activation", Immunol Res. 2002;26(1-3):303-8.		
PW		Gessner et al, " Biologic functions and signaling of the interleukin-4 receptor complexes", Immunobiology. 2000 Jan;201(3-4):285-307		
PW		Croft M, "Costimulation of T cells by OX40, 4-1BB, and CD27", Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):265-73		
PW		Hirano T, "Interleukin 6 and its receptor: ten years later", Int Rev Immunol. 1998;16(3-4):249-84.		
PW		Asadullah et al, " Interleukin-10 therapy--review of a new approach", Pharmacol Rev. 2003 Jun;55(2):241-69.		
PW		Meuller et al, " Structure, binding, and antagonists in the IL-4/IL-13 receptor system", Biochim Biophys Acta. 2002 Nov 11;1592(3):237-50.		
PW		VanderSpek et al, " Structure function analysis of interleukin 7: requirement for an aromatic ring at position 143 of helix D", Cytokine. 2002 Mar 7;17(5):227-33.		
PW		Kotenko SV, "The family of IL-10-related cytokines and their receptors: related, but to what extent?", Cytokine Growth Factor Rev. 2002 Jun;13(3):223-40		
PW		Wrana JL, "TGF-beta receptors and signalling mechanisms", Miner Electrolyte Metab. 1998;24(2-3):120-30		
PW		Kwon et al, " 4-1BB: still in the midst of darkness", Mol Cells. 2000 Apr 30;10(2):119-26.		
PW		Miyazono K, "TGF-beta receptors and signal transduction", Int J Hematol. 1997 Feb;65(2):97-104.		
PW		Brattain et al, " The type II transforming growth factor-beta receptor as a tumor-suppressor gene", Curr Opin Oncol. 1996 Jan;8(1):49-53.		
PW		Bihl et al, " Identification of a novel IL-6 isoform binding to the endogenous IL-6 receptor", Am J Respir Cell Mol Biol. 2002 Jul;27(1):48-56.		
PW		Maulik et al, " Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition", Cytokine Growth Factor Rev. 2002 Feb;13(1):41-59.		
PW		Gorgun et al, " Altered biological activity associated with C-terminal modifications of IL-7", Cytokine. 2002 Oct 7;20(1):17-22.		
PW		Mark et al, " Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding", J Biol Chem. 1992 Dec 25;267(36):26166-71.		
PW		Mould et al, " Molecular basis of ligand recognition by integrin alpha Sbeta 1. I. Specificity of ligand binding is determined by amino acid sequences in the second and third NH2-terminal repeats of the alpha subunit", J Biol Chem. 2000 Jul 7;275(27):20324-36.		
PW		Moustakas et al, " Smad regulation in TGF-beta signal transduction", J Cell Sci. 2001 Dec;114(Pt 24):4359-69		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



© 2014 by JBL Publications

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**1. Applicant's unique citation designation number (optional). 2. Applicant Is to place a check mark here if English language Translation is attached.**


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

**SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

If you need

8/7/06



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.  
**SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/764,833
Filing Date	January 27, 2004
First Named Inventor	AYALON-SOFFER Michal et al
Group Art Unit	1631
Examiner Name	P. WHALEY

Attorney Docket Number 27256

Sheet

Of

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PW	10	Tullo et al. "Reorganization and Merging of the EMBL and GenBank Keyword Indexes in A Tree Structure for More Efficient Retrieval of Nucleic Acid Sequences", Protein Sequences and Data Analysis, 3: 327-334, 1990.	
PW	11	Shoshan et al. "Designing Oligo Libraries Taking Alternative Splicing Into Account", Proc. SPIE., 4266: 86-95.	
PW	12	Michel et al. "Identification of A Novel IL-6 Isoform Binding to Endogenous IL-6 Receptor", Annual Journal Respir. Cell Molecular Biology, 27: 48-56, 2002.	
PW	13	Croft "Costimulatory Members of the TNFR Family: Keys to Effective T-Cell Immunity?" Nature Reviews, 3: 609-, 2003.	
PW	14	Aigner et al. "Expression of A Truncated 100 kDa HER2 Splice Variants Acts as An Endogenous Inhibitor of Tumour Cell Proliferation", Oncogene, 20(17): 2101-2111, 2001.	
PW	15	Gebhardt et al. "Differential Expression of Alternatively Spliced C-Erb-B-2 mRNA in Primary Tumors, Lymph Node Metastases, and Bone Marrow Micrometastases From Breast Cancer Patients", Biochemical and Biophysical Research Communications, 247(2): 319-323, 1998.	
PW	16	Kwong et al. "A Novel Splice Variant of HER2 With Increased Transformation Activity", Molecular Carcinogenesis, 23(2): 62-68, 1988.	
PW	17	Azios et al. "Expression of Herstatin, An Autoinhibitor of HER-2/Neu, Inhibits Transactivation of HER-3 by HER-2 and Blocks EGF Activation of the EGF Receptor", Oncogene, 20(37): 5199-5232, 2001.	
PW	18	Strausberg et al. "Homo Sapiens Ubiquitin-Conjugating Enzyme E2C, mRNA (cDNA Clone IMAGE: 5574059), Partial Cds", Database EMBL 'Online! Database Accession No. BC032677, 2202. See: "Generation and Initial Analysis of More Than 15,000 Full-Length Human and Mouse cDNA Sequences", Proc. Natl. Acad. Sci. USA, 99(26): 16899-16903, 2002.	
PW	19	??? "AGENCOURT_6578352 NIH_MGC_41 Homo Sapiens cDNA Clone IMAGE: 5467535 5', mRNA Sequence", Database EMBL 'Online!, Database Accession No. BM556795, 2002.	
PW	20	??? "AGENCOURT_7952308 NIH_MGC_72 Homo Sapiens cDNA Clone IMAGE: 6149711 5', mRNA Sequence", Database EMBL 'Online!, Database Accession No. BU171488, 2002.	
PW	21	Townsley et al. "Dominant-Negative Cyclin-Selective Ubiquitin Carrier Protein E2-C/UBCH10 Blocks Cells in Metaphase", Proc. Natl. Acad. Sci. USA, 94(6): 2362-2367, 1997.	
PW	22	Schlegel et al. "Human Cervical Cancer Cell Marker Protein SEQ ID NO: 228", Database Geneseq 'Online!, Database Accession No. ABR92159, 2003. & WO 02/101075, 2002.	
PW	23	Okamoto et al. "UbcH10 Is the Cancer-Related E2 Ubiquitin-Conjugating Enzyme", Cancer Research, 63(14): 4167-4173, 2003.	
PW	24	??? "OTTHUMP00000031654 (Fragment)", Database EMBL, Database Accession No. Q9BQP0, 2001. Abstract.	
PW	25	Reeck et al. "'Homology' in Proteins and Nucleic Acids: A Terminology Muddle and A Way Out of It", Cell, 50: 667, 1987.	
PW	26	??? "AGENCOURT_785234 NIH_MGC_67 Homo Sapiens cDNA Clone IMAGE: 6140098 5', mRNA Sequence", Database EMBL 'Online!, Database Accession No. BU169315, 2002.	

PW	27	Krawczak et al. "The Mutational Spectrum of Single Base-Pair Substitutions in mRNA Splice Junctions of Human Genes: Causes and Consequences", Human Genetics, 90: 41-54, 1992.	
PW	28	Boguski et al. "ESTablishing A Human Transcript Map", Nature Genetics, 10: 369-371, 1995.	
PW	29	Schena et al. "Quantitative Monitoring of Gene Expression Patterns With A Complementary DNA Microarray", Science, 270: 467-470, 1995.	
PW	30	Velculescu et al. "Serial Analysis of Gene Expression", Science, 270: 484-487, 1995.	
PW	31	Hillier et al. "Generation and Analysis of 280,000 Human Expressed Sequence Tags", Genome Research, P. 807-828.	
PW	32	Dwight et al. "Saccharomyces Genome Database (SGD) Provides Secondary Gene Annotation Using the Gene Ontology (GO)", Nucleic Acids Research, 30(1): 69-72, 2002.	
PW	33	Matloubian et al. "A Transmembrane CXC Chemokine Is A Ligand for HIV-Coreceptor Bonzo", Nature Immunology, 1(4): 298-304, 2000.	
PW	34	David et al. "Unusual Alternative Splicing Within the Human Kallikrein Genes KLK2 and KLK3 Gives Rise to Novel Prostate-Specific Proteins", The Journal of Biological Chemistry, 277(20): 18084-18090; 2002.	
PW	35	Camargo et al. "The Contribution of 700,000 ORF Sequence Tags to the Definition of the Human Transcriptome", PNAS, 98(21): 12103-12108, 2001.	
PW	36	Caron et al. "The Human Transcriptome Map: Clustering of Highly Expressed Genes in Chromosomal Domains", Science, 291: 1289-1292, 2001.	
PW	37	Audic et al. "The Significance of Digital Gene Expression Profiles", Genome Research, 7: 986-995, 1997.	
PW	38	Huminiecki et al. "In Silico Cloning of Novel Endothelial-Specific Genes", Genome Research, 10: 1796-1806, 2000.	
PW	39	Kawamoto et al. "BodyMap: A Collection of 3' ESTs for Analysis of Human Gene Expression Information", Genome Research, 10: 1817-1827, 2000.	
PW	40	Liu et al. "A Mechanism for Exon Skipping Caused by Nonsense or Missense Mutations in BRCA1 and Other Genes", Nature Genetics, 27: 55-58, 2001.	
PW	41	Brett et al. "EST Comparison Indicates 38% of Human mRNAs Contain Possible Alternative Splice Forms", FEBS Letters, 474: 83-86, 2000.	
PW	42	Croft et al. "ISIS, the Intron Information System, Reveals the High Frequency of Alternative Splicing in the Human Genome", Nature Genetics, 24: 340-341, 2000.	
PW	43	Burset et al. "Analysis of Canonical and Non-Canonical Splice Sites in Mammalian Genomes", Nucleic Acids Research, 28(21): 4364-4375, 2000.	
PW	44	Boguski "Biosequence Exegesis", Science, 286: 453-455, 1999.	
PW	45	Doherty et al. "The HER-2/Neu Receptor Tyrosine Kinase Gene Encodes A Secreted Autoinhibitor", Medical Sciences, 96(19): 10869-10874, 1999.	
PW	46	Nahta et al. "Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention", The Oncologist, 8(1): S-17, 2003.	
PW	47	Younes et al. "Labelled Oligonucleotides as Radiopharmaceuticals: Pitfalls, Problems and Perspectives", Current Pharmaceutical Design, 8: 1451-1466, 2002.	
PW	48	Sazani et al. "Modulation of Alternative Splicing by Antisense Oligonucleotides", Progress in Molecular and Subcellular Biology, 31: 217-239, 2003.	

Signature	/Pablo Whaley/ (08/07/2006)	Considered
-----------	-----------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).  Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.